Literature DB >> 24101301

Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine.

Christine M Emnett1, Lawrence N Eisenman, Amanda M Taylor, Yukitoshi Izumi, Charles F Zorumski, Steven Mennerick.   

Abstract

Memantine and ketamine, voltage- and activation-dependent channel blockers of N-methyl-d-aspartate (NMDA) receptors (NMDARs), have enjoyed a recent resurgence in clinical interest. Steady-state pharmacodynamic differences between these blockers have been reported, but it is unclear whether the compounds differentially affect dynamic physiologic signaling. In this study, we explored nonequilibrium conditions relevant to synaptic transmission in hippocampal networks in dissociated culture and hippocampal slices. Equimolar memantine and ketamine had indistinguishable effects on the following measures: steady-state NMDA currents, NMDAR excitatory postsynaptic current (EPSC) decay kinetics, progressive EPSC inhibition during repetitive stimulation, and extrasynaptic NMDAR inhibition. Therapeutic drug efficacy and tolerability of memantine have been attributed to fast kinetics and strong voltage dependence. However, pulse depolarization in drug presence revealed a surprisingly slow and similar time course of equilibration for the two compounds, although memantine produced a more prominent fast component (62% versus 48%) of re-equilibration. Simulations predicted that low gating efficacy underlies the slow voltage-dependent relief from block. This prediction was empirically supported by faster voltage-dependent blocker re-equilibration with several experimental manipulations of gating efficacy. Excitatory postsynaptic potential-like voltage commands produced drug differences only with large, prolonged depolarizations unlikely to be attained physiologically. In fact, we found no difference between drugs on measures of spontaneous network activity or acute effects on plasticity in hippocampal slices. Despite indistinguishable synaptic pharmacodynamics, ketamine provided significantly greater neuroprotection from damage induced by oxygen glucose deprivation, consistent with the idea that under extreme depolarizing conditions, the biophysical difference between drugs becomes detectable. We conclude that despite subtle differences in voltage dependence, during physiologic activity, blocker pharmacodynamics are largely indistinguishable and largely voltage independent.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24101301      PMCID: PMC3834148          DOI: 10.1124/mol.113.089334

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  57 in total

1.  Tonic NMDA receptor-mediated current in prefrontal cortical pyramidal cells and fast-spiking interneurons.

Authors:  Nadezhda V Povysheva; Jon W Johnson
Journal:  J Neurophysiol       Date:  2012-01-11       Impact factor: 2.714

Review 2.  NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders.

Authors:  Charles F Zorumski; Yukitoshi Izumi
Journal:  Neurosci Biobehav Rev       Date:  2012-01-02       Impact factor: 8.989

Review 3.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 4.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

5.  Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses.

Authors:  Peng Xia; Huei-sheng Vincent Chen; Dongxian Zhang; Stuart A Lipton
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

6.  Zinc effects on NMDA receptor gating kinetics.

Authors:  Stacy A Amico-Ruvio; Swetha E Murthy; Thomas P Smith; Gabriela K Popescu
Journal:  Biophys J       Date:  2011-04-20       Impact factor: 4.033

7.  Presynaptic silencing is an endogenous neuroprotectant during excitotoxic insults.

Authors:  Joshua Hogins; Devon C Crawford; Xiaoping Jiang; Steven Mennerick
Journal:  Neurobiol Dis       Date:  2011-05-14       Impact factor: 5.996

8.  Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.

Authors:  Thomas Papouin; Laurent Ladépêche; Jérôme Ruel; Silvia Sacchi; Marilyne Labasque; Marwa Hanini; Laurent Groc; Loredano Pollegioni; Jean-Pierre Mothet; Stéphane H R Oliet
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

9.  Synaptic NMDA receptors mediate hypoxic excitotoxic death.

Authors:  Christine M Wroge; Joshua Hogins; Larry Eisenman; Steven Mennerick
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

10.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

View more
  29 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

2.  Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.

Authors:  Eric J Lenze; Nuri B Farber; Evan Kharasch; Julie Schweiger; Michael Yingling; John Olney; John W Newcomer
Journal:  World J Biol Psychiatry       Date:  2016-02-26       Impact factor: 4.132

3.  Ketamine: NMDA Receptors and Beyond.

Authors:  Charles F Zorumski; Yukitoshi Izumi; Steven Mennerick
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

4.  NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model.

Authors:  Shu-Ichi Okamoto; Olga Prikhodko; Juan Pina-Crespo; Anthony Adame; Scott R McKercher; Laurence M Brill; Nobuki Nakanishi; Chang-Ki Oh; Tomohiro Nakamura; Eliezer Masliah; Stuart A Lipton
Journal:  Neurobiol Dis       Date:  2019-03-27       Impact factor: 5.996

5.  Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking.

Authors:  Katherine M Holleran; Hadley H Wilson; Tracy L Fetterly; Rebecca J Bluett; Samuel W Centanni; Rachel A Gilfarb; Lauren E R Rocco; Sachin Patel; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2016-01-11       Impact factor: 7.853

Review 6.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

7.  Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function.

Authors:  Yukitoshi Izumi; Charles F Zorumski
Journal:  Neuropharmacology       Date:  2014-08-13       Impact factor: 5.250

Review 8.  Organization, control and function of extrasynaptic NMDA receptors.

Authors:  Thomas Papouin; Stéphane H R Oliet
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-10-19       Impact factor: 6.237

Review 9.  24(S)-Hydroxycholesterol as a Modulator of Neuronal Signaling and Survival.

Authors:  Min-Yu Sun; Andrew J Linsenbardt; Christine M Emnett; Lawrence N Eisenman; Yukitoshi Izumi; Charles F Zorumski; Steve Mennerick
Journal:  Neuroscientist       Date:  2015-01-27       Impact factor: 7.519

Review 10.  Duality of Antidepressants and Neuroprotectants.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2015-11-27       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.